<DOC>
	<DOCNO>NCT02406326</DOCNO>
	<brief_summary>This multi centre , prospective trial . 250 patient enrol study . ( 10 patient per centre involve approximately 25 centre ) . Patients follow clinically twelve month post-procedure 1 month , 6 month &amp; 12 month . All patient repeat angiography 8 month . Clinical follow-up maintain year 3 &amp; 5 post-implant .</brief_summary>
	<brief_title>An Evaluation BioMime™ - Sirolimus Eluting Coronary Stent Multi- Centre Study The BioMime™1 Trial</brief_title>
	<detailed_description>This multi centre , prospective observational study . 250 patient enrol study . 10 patient per centre involve approximately 25 centre . All patient follow twelve month post-procedure . All patient repeat angiography assessment 8 month . An additional clinical follow-up maintain year 3 &amp; 5 post-implant . Approximately 250 patient obstructive coronary artery disease vessel size ≥2.5 ≤3.5 mm diameter visual estimate meet eligibility criterion treat Sirolimus Eluting Stent . It anticipate total length study 16 month : 4 month complete patient enrollment 12 month angiographic follow-up .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . The patient must ≥18 year age ; 2 . Patient acceptable candidate PTCA , Stenting , Emergent CABG ; 3 . Symptomatic ischemic heart disease ( CCS class 14 , Braunwald class IB , IC , IIB , IIC , IIIB , IIIC ) and/or objective evidence myocardial ischemia ; 4 . TIMI ( Thrombolysis In Myocardial Infarction ) flow grade ≥ 2 ; 5 . C.T.O 's ( Chronic Total Occlusions ) Bifurcation Lesions may also attempt ; 6 . Target lesion stenosis &gt; 50 % &lt; 100 % ; 7 . Target lesion de novo ; 8 . Target lesion ≤ 35mm length ( visual estimation ) treat ( cover ) one single study stent ( 13 40mm length ) 9 . Target lesion locate major epicardial coronary vessel reference ≥ 2.5 ≤ 3.5mm diameter ( visual estimation ) 10 . Target lesion cover one stent , overlap allow ( lesion stent ratio least 1.5 ) 11 . The patient and/or legal representative inform nature study agree provision provide write informed consent . General exclusion criterion : 1 . Women childbearing potential ; 2 . Impaired renal function ( creatinine &gt; 2.0 mg/dl 180 μmol/l ) ; 3 . Any patient platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 , WBC &lt; 3,000 cells/mm3 , document suspect liver disease ( include laboratory evidence Hepatitis ; 4 . Recipient organ ( Heart , Kidney , Lung Liver ) transplant ; 5 . History CVA TIA within last 3 month 6 . Patient concomitant disease life expectancy le 12 month ; 7 . Known allergy contraindication mTOR inhibitor class drug ( Sirolimus ) , Aspirin , Clopidogrel Bisulphate ( Plavix® ) , Heparin , Cobalt Chromium/Nickel , contrast medium ; 8 . Any significant medical condition investigator 's opinion may interfere patient 's optimal participation study active infection peptic ulcer upper GI bleeding ; 9 . Currently participate investigational drug another device study , subject inclusion another investigational drug another device study followup . 10 . Clinically relevant contraindication aspirin , heparin , clopidogrel bisulphate , include thrombocytopenia , neutropenia , leukopenia 11 . Patients Cardiogenic Shock . Angiographic Exclusion criterion : 1 . Left main coronary artery disease ≥ 50 % stenosis , 2 . Angiographic evidence thrombus ( thrombus large half diameter vessel and/or require adjunctive intervention Angiojet , Exciser , Thrombolysis , etc . ) , 3 . Left Ventricular Ejection Fraction ≤30 % , 4 . Saphenous Vein Graft Interventions , ( S.V.G 's ) 5 . Patients present ongoing Acute Myocardial Infarction ( AMI ) , 6 . Patients undergone PCI within 48 hour AMI episode .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>